Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

June 9, 2020 · Cell Sourcing, COVID-19, Industry Updates, Q&A, Supply Chain

Can cell therapies unlock the COVID-19 mystery?

The promise of MSC therapies to treat deadly manifestations of cytokine storms

May 29, 2020 · COVID-19, Emerging Science, Industry Updates

How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

May 21, 2020 · Cell Sourcing, COVID-19, Industry Updates, Supply Chain

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

April 10, 2020 · Cell Sourcing, COVID-19, Q&A, Supply Chain

Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?

Why reliance on a small subset of donors could introduce risk for companies

March 12, 2020 · Cell Sourcing

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Why established systems and relationships matter

February 20, 2020 · COVID-19, Industry Updates, Q&A, Supply Chain

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies

February 10, 2020 · Cell Sourcing, Emerging Science, Industry Updates

Advancements in Cell and Gene Therapy: 2019 Year-in-Review

January 8, 2020 · Emerging Science, Industry Updates